Literature DB >> 8720474

Melatonin analogues as agonists and antagonists in the circadian system and other brain areas.

S W Ying1, B Rusak, P Delagrange, E Mocaer, P Renard, B Guardiola-Lemaitre.   

Abstract

We studied the effects of drugs related to melatonin on neuronal firing activity in the suprachiasmatic nucleus, intergeniculate leaflet and other brain areas in urethane-anesthetized Syrian hamsters. We tested melatonin and two naphthalenic derivatives of melatonin, a putative agonist (S20098: N-[2-(7-methoxy-1-naphthyl)ethyl]acetamide), and a putative antagonist (S20928: N-[2-(1-naphthyl)ethyl]cyclobutyl carboxamide). Both melatonin and S20098 given intraperitoneally (i.p.) were able to suppress firing rates of cells in a similar dose-dependent manner, but the effects of S20098 were longer lasting. Iontophoresis of melatonin dose dependently depressed spontaneous and light-evoked activity of cells in the suprachiasmatic nucleus and intergeniculate leaflet, while iontophoresis of S20098 was relatively ineffective, probably because it is a poorly charged compound. S20928 (2.0-10 mg/kg, i.p.) alone decreased firing rates of light-sensitive cells by 25-50% for 5-30 min in the suprachiasmatic nucleus and intergeniculate leaflet; however, low doses (< 2.0 mg/kg) of S20928 partially blocked the effects of melatonin agonists on most cells. The non-selective serotonin antagonist metergoline did not block the effects of either melatonin agonist. Both melatonin agonists and antagonists were less effective when applied to cells in the hippocampus and dorsal lateral geniculate nucleus. These results indicate that S20098 is an agonist acting probably on melatonin receptors in the Syrian hamster brain. S20928 may have mixed agonist/antagonist properties, but at low doses appears to function as an antagonist at melatonin receptors in the suprachiasmatic nucleus and intergeniculate leaflet.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8720474     DOI: 10.1016/0014-2999(95)00684-2

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  25 in total

Review 1.  Circadian rhythms and mood regulation: insights from pre-clinical models.

Authors:  Colleen A McClung
Journal:  Eur Neuropsychopharmacol       Date:  2011-08-11       Impact factor: 4.600

2.  The future of antidepressant pharmacotherapy.

Authors:  David Baldwin; Chris Thompson
Journal:  World Psychiatry       Date:  2003-02       Impact factor: 49.548

Review 3.  Melatonin and its receptors: a new class of sleep-promoting agents.

Authors:  Karl Doghramji
Journal:  J Clin Sleep Med       Date:  2007-08-15       Impact factor: 4.062

Review 4.  Circadian genes, rhythms and the biology of mood disorders.

Authors:  Colleen A McClung
Journal:  Pharmacol Ther       Date:  2007-02-28       Impact factor: 12.310

Review 5.  Review of pharmacological treatment in mood disorders and future directions for drug development.

Authors:  Xiaohua Li; Mark A Frye; Richard C Shelton
Journal:  Neuropsychopharmacology       Date:  2011-09-07       Impact factor: 7.853

Review 6.  MT1 and MT2 Melatonin Receptors: A Therapeutic Perspective.

Authors:  Jiabei Liu; Shannon J Clough; Anthony J Hutchinson; Ekue B Adamah-Biassi; Marina Popovska-Gorevski; Margarita L Dubocovich
Journal:  Annu Rev Pharmacol Toxicol       Date:  2015-10-23       Impact factor: 13.820

Review 7.  Future antidepressants: what is in the pipeline and what is missing?

Authors:  Fokko J Bosker; Ben H C Westerink; Thomas I F H Cremers; Marjolein Gerrits; Marieke G C van der Hart; Sjoukje D Kuipers; Gieta van der Pompe; Gert J ter Horst; Johan A den Boer; Jakob Korf
Journal:  CNS Drugs       Date:  2004       Impact factor: 5.749

8.  Spike activity of neurons in the lateral hypothalamus in rats during microiontophoretic application of melatonin and noradrenaline.

Authors:  S S Pertsov; A F Meshcheryakov; R G Glushkov; K V Sudakov
Journal:  Neurosci Behav Physiol       Date:  2004-06

Review 9.  Role of the melatonin system in the control of sleep: therapeutic implications.

Authors:  Seithikurippu R Pandi-Perumal; Venkatramanujan Srinivasan; D Warren Spence; Daniel P Cardinali
Journal:  CNS Drugs       Date:  2007       Impact factor: 5.749

10.  Melatonin inhibits nitrate tolerance in isolated coronary arteries.

Authors:  Stephen T O'Rourke; Hana Hammad; Philippe Delagrange; Elizabeth Scalbert; Paul M Vanhoutte
Journal:  Br J Pharmacol       Date:  2003-08       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.